Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.
EPIC-26
Health-related Quality of Life
Patient-reported outcomes
Prostate cancer
Validation
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
05
2019
accepted:
04
09
2019
pubmed:
26
9
2019
medline:
6
8
2021
entrez:
26
9
2019
Statut:
ppublish
Résumé
For patients with prostate cancer, validated and reliable instruments are essential for measuring patient-reported outcomes. The aim of this study was to validate the German version of the widely established Expanded Prostate Cancer Index Composite with 26 items (EPIC-26). A German translation of the original questionnaire was tested in 3094 patients with localized or locally advanced (any T, any N and M0) prostate cancer with treatment intent (including radical prostatectomy, brachytherapy, active surveillance, watchful waiting). They completed the EPIC-26 questionnaire before treatment. A total of 521 of them also completed a questionnaire 12 months afterward. Internal consistency, sensitivity to change, and construct validity were assessed. The internal consistency of all domains was sufficient (Cronbach's alpha between 0.64 and 0.93). Item-to-scale correlation coefficients showed acceptable associations between items and their domain score (all > 0.30), with the lowest scores for "bloody stools" (r = 0.37) and "breast problems" (r = 0.32). Confirmatory and exploratory factor analysis confirmed the five-dimension structure of the EPIC-26 (comparative fit index 0.95). Psychometric evaluation suggests that the German version of the EPIC-26 is a well-constructed instrument for measuring patient-reported health-related symptoms in patients with prostate cancer.
Identifiants
pubmed: 31552467
doi: 10.1007/s00345-019-02949-7
pii: 10.1007/s00345-019-02949-7
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-25Références
Zentrum für Krebsregisterdaten and Gesellschaft der epidemiologischen Krebsregister in Deutschland (2017) Krebs in Deutschland für 2013/2014. Robert Koch-Institut, Berlin
Trama A et al (2015) Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: results from the EUROCARE-5 study. Eur J Cancer 51(15):2206–2216
doi: 10.1016/j.ejca.2015.07.027
Litwin MS et al (1995) Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273(2):129–135
doi: 10.1001/jama.1995.03520260051032
Madalinska JB et al (2001) Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19(6):1619–1628
doi: 10.1200/JCO.2001.19.6.1619
Sanda MG et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250–1261
doi: 10.1056/NEJMoa074311
Wei JT et al (2000) Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56(6):899–905
doi: 10.1016/S0090-4295(00)00858-X
Szymanski KM et al (2010) Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 76(5):1245–1250
doi: 10.1016/j.urology.2010.01.027
Schmidt S et al (2014) Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments. Qual Life Res 23(8):2169–2181
doi: 10.1007/s11136-014-0678-8
Lam WWT et al (2017) Psychometric assessment of the Chinese version of the abbreviated expanded prostate cancer index composite (EPIC-26) and the clinical practice version (EPIC-CP) in chinese men with prostate cancer. J Pain Symptom Manage 53(6):1085–1090
doi: 10.1016/j.jpainsymman.2017.02.010
Fossa SD et al (2016) Psychometric testing of the Norwegian version of the expanded prostate cancer index composite 26-item version (EPIC-26). Scand J Urol 50(4):280–285
doi: 10.3109/21681805.2016.1163617
Vigneault E et al (2017) Validation of the French-Canadian version of the expanded prostate cancer index composite (EPIC) in a French-Canadian population. Can Urol Assoc J 11(12):404–410
doi: 10.5489/cuaj.4428
Beyer B et al (2015) “Expanded prostate cancer index composite” (EPIC-26): Funktionelles Behandlungsergebnis bei Patienten mit lokalisiertem Prostatakarzinom. Urologe A 54(11):1591–1595
doi: 10.1007/s00120-015-3922-0
Umbehr MH et al (2018) The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation. Health Qual Life Outcomes 16(1):36
doi: 10.1186/s12955-018-0859-1
Evans SM et al (2017) Cohort profile: the TrueNTH Global Registry: an international registry to monitor and improve localised prostate cancer health outcomes. BMJ Open 7(11):e017006
doi: 10.1136/bmjopen-2017-017006
Martin NE et al (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67(3):460–467
doi: 10.1016/j.eururo.2014.08.075
ICHOM ( 2017) Localized prostate cancer data collection reference guide. https://ichom.org/files/medical-conditions/localized-prostate-cancer/localized-prostate-cancer-reference-guide.pdf . Accessed 23 Sep 2019
Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334
doi: 10.1007/BF02310555
Cohen J (1988) Statistical power analysis for the behavioral sciences. N.J.L. Erlbaum Associates, Hillsdale
Nunnally CJ, Bernstein I (1994) Psychometric Theory. McGraw-Hill, New York
Reeve Bryce B et al (2018) Symptom and function profiles of men with localized prostate cancer. Cancer 124(13):2832–2840
doi: 10.1002/cncr.31401
Nunnally JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
German Guideline Program in Oncology (2018) ed. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Version 5.0, 1. Aktualisierung, AWMF-Registernummer: 043/022OL
Wei J, Dunn R, Litwin M, Sandler H, and Sanda M (2000) Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899–905